Custom service

Peptide-Antibody Conjugation

Conjugate peptides to monoclonal antibodies for competitive and capture reagents

Turnaround: 4–6 weeksTypical scale: 0.1–50 mg conjugate per batchChemistry options: lysine and Fc-glycan domain coupling; site-specific conjugation at engineered cysteines; degree-of-labeling (DOL) control

Teams come to this service when they need to conjugate peptides to monoclonal antibodies for competitive and capture reagents. We typically start from lysine and Fc-glycan domain coupling, add site-specific conjugation at engineered cysteines where the application demands it, and close the loop with degree-of-labeling (DOL) control so the final antibody conjugate with DOL and binding-activity QC behaves consistently across lots.

Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 4–6 weeks timeline holds in practice.

Competitive ELISA and blocking-assay development

Bispecific capture reagent prototyping

Antibodies supplied without any stability or formulation data

Conjugates whose payload cannot tolerate aqueous coupling conditions

Every conjugation batch is documented from vial to vial: carrier lot, payload lot, reagent lots, reaction conditions and purification chromatograms. The release package contains the loading ratio measured by an orthogonal method (UV, ICP-MS or amino-acid analysis), identity by mass spectrometry where the conjugate permits it, and residual-free-payload data.

Service Highlights

  • Lysine and Fc-glycan domain coupling as the default route, with site-specific conjugation at engineered cysteines held as a proven fallback
  • Degree-of-labeling (DOL) control worked into the design where the application requires it
  • Carrier and payload compatibility screened in a small feasibility batch before full material is committed
  • Analytical confirmation of every intermediate before the final release
  • Unreacted payload driven below the detection limit of the release assay before purification is closed
  • Antibody conjugate with DOL and binding-activity QC delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Scope & design

    We review the payload, the carrier and the intended assay or study, and propose between lysine and Fc-glycan domain coupling and site-specific conjugation at engineered cysteines as candidate routes.

  2. Feasibility screen

    A milligram-scale screen compares loading, residual payload and activity across the candidate conditions.

  3. Production conjugation

    The selected condition is executed at project scale with in-process sampling at fixed time points.

  4. Purification

    Size-exclusion, dialysis or magnetic separation removes free payload and by-products.

  5. Characterization & release

    Identity, loading ratio and functional activity are measured against the agreed specification.

  6. Documentation & hand-off

    Antibody conjugate with DOL and binding-activity QC is packaged with the full batch record, released for shipment after QC sign-off.

Specifications & timeline

Turnaround
4–6 weeks
Typical scale
0.1–50 mg conjugate per batch
Chemistry options
lysine and Fc-glycan domain coupling; site-specific conjugation at engineered cysteines; degree-of-labeling (DOL) control
Deliverable
Antibody conjugate with DOL and binding-activity QC
QC package
HPLC/SEC trace, MALDI-TOF or ESI-MS, UV/Vis or ICP-MS loading ratio
Shipping
Blue ice or dry ice as the payload requires, with a cold-chain manifest

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.